Bionomics Limited (NASDAQ:BNOX) Short Interest Update

Bionomics Limited (NASDAQ:BNOX) was the recipient of a significant increase in short interest in November. As of November 15th, there was short interest totalling 384,300 shares, an increase of 101.9% from the October 31st total of 190,300 shares. Based on an average trading volume of 9,290,000 shares, the days-to-cover ratio is currently 0.0 days.

Bionomics Stock Performance

Shares of BNOX stock traded up $0.02 on Thursday, hitting $0.30. The stock had a trading volume of 233,884 shares, compared to its average volume of 2,980,388. The business has a 50 day moving average of $0.34 and a 200 day moving average of $0.60. Bionomics has a 12-month low of $0.18 and a 12-month high of $1.66.

Analyst Ratings Changes

Several research firms recently issued reports on BNOX. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Bionomics in a research report on Thursday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Bionomics in a research report on Friday, November 15th.

Hedge Funds Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC purchased a new position in shares of Bionomics Limited (NASDAQ:BNOX) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent quarter. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.